Stock Analysis

Arcadia Biosciences Full Year 2023 Earnings: Misses Expectations

Simply Wall St

April 01, 2024

Arcadia Biosciences (NASDAQ:RKDA) Full Year 2023 Results

Key Financial Results

Revenue: US$5.33m (down 28% from FY 2022).
Net loss: US$13.2m (loss widened by 24% from FY 2022).
US$10.64 loss per share.

revenue-and-expenses-breakdown — NasdaqCM:RKDA Revenue and Expenses Breakdown April 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Arcadia Biosciences Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 16%.

The primary driver behind last 12 months revenue was the United States segment contributing a total revenue of US$5.03m (94% of total revenue). Notably, cost of sales worth US$4.24m amounted to 80% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to US$14.5m (100% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$261.0k. Explore how RKDA's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 2.7% growth forecast for the Food industry in the US.

Performance of the American Food industry.

The company's shares are down 3.9% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 4 warning signs for Arcadia Biosciences (3 are potentially serious!) that you should be aware of.

Valuation is complex, but we're helping make it simple.

Find out whether Arcadia Biosciences is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.